Focus on human microbiome to fight liver cirrhosis
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.
BavenoVII Consensus Workshop sponsored by MICROB-PREDICT
MICROB-PREDICT supports this year`s BavenoVII Consensus Workshop. Baveno Workshops have been held every 5 years from 1990 till today. Each time, important advances have been made in understanding the pathophysiology of portal hypertension, as well as in developing new treatments and new strategies for the management of advanced cirrhosis and portal hypertension. See programme.More news
3rd General Assembly Meeting, Leuven, Belgium
Our first hybrid-GA meeting, taking place from 6-8 October 2021 in Leuven, Belgium has been successfully completed with 37 participants joining on-site, and over 20 participants remotely.
A lot of data has been presented with promising multiomics results to develop biomarkers to predict disease progression and response to treatment for patients suffering from cirrhosis and ACLF.